

A 3D rendering of protein structures, featuring a prominent blue ribbon structure and a smaller, more complex structure with many small spheres, all set against a light blue background.

3rd Targeted Protein Degradation Conference in Japan

Date: 29-31st July 2023

Venue: Shonan iPark (Fujisawa, Kanagawa)

This Agenda is a draft and subject to change prior to the conference,
including speakers, titles, and order

Day 1

Morning Session, Clinical Assets

45 min

Keynote Presentation

Title: TBD

Gwenn Hansen, CSO, Nurix Therapeutics, Inc.

25 min

Targeted Degradation of TRK for Cancer Therapy and Pain Management

Jialiang Wang, Executive VP of Operation, Cullgen, Inc.

25 min

Discovery and Clinical Development of Targeted Protein Degraders and Degradation-Antibody Conjugates (DACs)

Koichi Ito, Senior Director Biology, Prelude Therapeutics

Afternoon Session 1, Technologies

25 min

Development of Highly Active PROTACs and Research on Expanding PROTAC Molecular Modalities

Hidetomo Yokoo, Chief, Division of Organic Chemistry, National Institute of Health and Science (NIHS)

25 min

Advancing Degradation Discovery and Expanding The Landscape of E3 Ligases by RaPPIDS™

Kanae Gamo, CSO, FIMECS, Inc.

25 min

Characterization of PROTAC Specificity and Endogenous Protein Interactomes Using ProtacID

Suman Shrestha, Postdoctoral Researcher, Princess Margaret Cancer Centre

Afternoon Session 2, Technologies

25 min

Protein Knockdown Mediated by Auxin-Inducible Degron (AID) Technology

Masato Kanemaki, Professor, Department of Chromosome Science, National Institute of Genetics

25 min

Linker Free PROTACs

Hai Rao, Professor, Southern University of Science and Technology

25 min

Induction of lysosomal degradation by IAP-based PROTACs, SNIPERs

Mikihiko Naito, Professor, Graduate School of Pharmaceutical Sciences, University of Tokyo

30 min

Sponsor Presentation

WuXi AppTec

Reception Party at The Venue

Day 2

Morning Session 1, Clinical and Non-Clinical Assets

25 min

Brain-penetrant molecular glue degraders targeting ALK via a novel degron: A potential therapeutic approach for ALK-positive NSCLC

Zheng Wang, Principal Scientist, Bristol Myers Squibb

25 min

Title TBD

Veronica Campbell, Senior Director, Immunology, Kymera Therapeutics

25 min

Title TBD

Chinatsu Sakata-Sakurai, Head of Oncology Research, Astellas Pharma

Morning Session 2, Anti-Bacterial Degradors

25 min

Bifunctional Molecules to Break Antimicrobial Resistance

Emilia Taylor, PhD Researcher, The University of Oxford

25 min

Development of Anti-Virulence Therapy Against Bacterial Infections.

Minsoo Kim, Associate Professor, Kyoto University

10 min

Sponsor Presentation

FUJIFILM

Afternoon Session 1, Technologies

25 min

Title: TBD

Jose Santos, Drug Discovery Leader, Nurix Therapeutics

25 min

MicDrop - Cellular DEL Screen in Droplets for TPD and beyond

Ken Yamada, Associate Director, Novartis Biomedical Research

Afternoon Session 2, Technologies

25 min

High-Throughput Proteomic Screening to Identify and Validate Novel Degradator Molecules and Targets

Henrik Daub, Founder and CSO, NEOsphere Biotechnologies

25 min

Title: TBD

Tasuku Ishida, Lead Scientist, Elix, Inc.

25 min

New approaches to PROTACs and Molecular Glues discovery combining AI, automated synthesis and innovative biology platform

Yann Gaston-Mathé, CEO and Co-Founder, Iktos

Evening Session, General

25 min

Title: TBD

Masako Imaoka, Daiichi Sankyo Co., Ltd.

25 min

Ten Years of Therapeutic TPD. What Have We Learnt and Where Next?

Ian Churcher, Chief Executive Officer, Janus Drug Discovery Consulting Ltd

45 min

Panel Discussion

Day 3

Morning Session 1, Non-Clinical Assets

25 min

Title: TBD

Lauren Veronica Albercht, Assistant Professor, University of California Irvine

25 min

Combining The Power of Protein Degraders With the Precision of Antibodies for Synergistic Potential Using Degradar-Antibody Conjugates (DACs)

Sang Hyun Lee, Vice President, Orum Therapeutics

25 min

Broad-Spectrum Efficacy of CEACAM6-Targeted ADC with BET Protein Degradar in Solid Cancer Models

Hiroyuki Kogai, Scientist, Eisai Co., Ltd.

10 min

Sponsor Presentation

Iktos

Morning Session 2, Molecular Glue

25 min

Innovative Drug Discovery Using Protein Degradar

Hyunsun Jo, Founder and CEO, Pin Therapeutics

25 min

Title: TBD,

Yong Cang, CSO and Co-founder, Degron Therapeutics

25 min

Title: TBD

Rohan Beckwith, VP Chemistry, Neomorph